Venus Remedies has consistently maintained impeccable standards in its distribution operations.
Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme.
Likewise, the companys net profit percentage to total revenue grew from 1.11% to 10.51% and the EBIDTA percentage to revenue from 12.41
The current market cap of the company is Rs611.87cr.
To introduce disruptive products over the next five years' covering key segments like pain management, gastroenterology, hygiene, stres
The company allotted 6,00,000 equity shares to promoter Pawan Chaudhary and 4,25,000 equity shares to another promoter Manu Chaudhary.
This innovative product has been commented to deliver a compelling total cost of ownership in that it prevents pre-activation, offers a
The company's four abstracts were accepted for poster presentations at the IDWeek 2018.
Check out the companies which will be in focus during trade today based on recent and latest news developments.
This is a negative news for the company.
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity